The Vasculitis Clinical Research Consortium (VCRC) was established in 2003 and in 5 years of rapid growth and productivity has become the major clinical research infrastructure in North America dedicated to the study of vasculitis. The VCRC is a founding member and leading force of the NIH Rare Diseases Clinical Research Network (RDCRN). By conducting a series of longitudinal cohort studies, biomarker discovery projects, multicenter clinical trials, and outcome measure development projects, the Consortium is addressing serious unmet medical and scientific needs for this group complex rare diseases. The VCRC currently has over 500 patients in clinical research on the following 6 types vasculitis: giant cell arteritis. Takayasu's arteritis, polyarteritis nodosa, Wegener's granulomatosis, microscopic polyangiitis, and Churg-Straus Syndrome. Each of these diseases are consider """"""""orphan"""""""" diseases. Additionally, partnership with patient advocacy groups has been a critical component to the success of t he VCRC. The VCRC electronic resources are important for patients worldwide. The VCRC Fellowship Program has successfully trained new clinical investigators, each of whom remains engaged in academic research in vasculitis. This proposal outlines a total of 13 separate clinical protocols with 10 associated studies of biomarkers . VCRC investigators have successfully obtained ancillary funding to allow for expansion of the Consortium's work. Sources of these funds include the NIH, the FDA, private foundations and the biopharmaceutical industry. This application seeks refunding of the VCRC to both support the critical administrative , laboratory, biostatistical cores and allow completion of ongoing projects, launch of exciting new scientific initiatives training of new investigators in clinical research in vasculitis, and expansion of the VCRC website.
The Vasculitis Clinical Research Consortium (VCRC) combines the clinical and scientific expertise of several major academic medical centers in North America to conduct a series of research projects in several types of vasculitis. Vasculitis is a serious but rare set of diseases and the combined efforts of the VCRC investigators will seek to address important unanswered questions about the causes and best treatments for vasculitis. The VCRC will also teach other physicians about vasculitis and will work closely with vasculitis patient advocacy groups.
|Bingham 3rd, Clifton O; Bartlett, Susan J; Merkel, Peter A et al. (2016) Using patient-reported outcomes and PROMIS in research and clinical applications: experiences from the PCORI pilot projects. Qual Life Res 25:2109-16|
|Kermani, Tanaz A; Cuthbertson, David; Carette, Simon et al. (2016) The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. J Rheumatol 43:1078-84|
|Sy, Alice; Khalidi, Nader; Dehghan, Natasha et al. (2016) Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Semin Arthritis Rheum 45:475-82|
|Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66|
|Tamura, Roy N; Krischer, Jeffrey P; Pagnoux, Christian et al. (2016) A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemp Clin Trials 46:48-51|
|Pagnoux, C; Carette, S; Khalidi, N A et al. (2015) Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33:S-77-83|
|Kermani, Tanaz A; Warrington, Kenneth J; Cuthbertson, David et al. (2015) Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. J Rheumatol 42:1213-7|
|Hatemi, Gulen; Ozguler, Yesim; Direskeneli, Haner et al. (2015) Current Status, Goals, and Research Agenda for Outcome Measures Development in BehÃ§et Syndrome: Report from OMERACT 2014. J Rheumatol 42:2436-41|
|Aydin, Sibel Zehra; Direskeneli, Haner; Sreih, Antoine et al. (2015) Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. J Rheumatol 42:2465-9|
|Dejaco, Christian; Oppl, Bastian; Monach, Paul et al. (2015) Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One 10:e0121737|
Showing the most recent 10 out of 59 publications